Atopic Dermatitis

Leung, Alexander K. C; Hon, Kam Lun; Robson, Wm. Lane M.

doi:10.1016/j.yapd.2007.03.013

Cited by 96 publications

(111 citation statements)

References 162 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…Keratinocytes are the main cells that constitute the epidermis of the skin and play a role in forming the skin barrier through division and differentiation. In case of skin diseases such as atopic dermatitis, a normal skin barrier is not produced and abnormal keratinocyte differentiation occurs; therefore, in such diseases, keratinocyte differentiation can be promoted to aid in the normal formation of the skin barrier (Leung et al, 2007).…”

Section: Discussionmentioning

confidence: 99%

Sophora japonica extracts accelerates keratinocyte differentiation through miR-181a

Kim¹,

Jun

Joo³

et al. 2018

biomed dermatol

View full text Add to dashboard Cite

Background: The Sophora japonica extracts contain flavonol triglycoside, isoflavonol, coumarone chromone, saponin, triterpene glucoside, phospholipids, alkaloids, amino acids, polysaccharides, and fatty acids. These components have physiological effects such as anti-infertility and anti-cancer activities. This study investigated the regulation of keratinocyte differentiation upon treatment with the S. japonica extracts in keratinocyte and the molecular cell biological mechanism involved. Methods: To determine whether the S. japonica extracts or troxerutin, which is its main component, regulates keratinocyte differentiation, quantitative real-time polymerase chain reaction (qRT-PCR) was performed on keratinocyte differentiation markers such as keratin 1 (K1), keratin 10 (K10), involucrin, and filaggrin after treatment with the S. japonica extracts. miR-181a knockdown confirmed that keratinocyte differentiation was regulated by increased miR-181a expression upon treatment with the S. japonica extracts or troxerutin.

show abstract

Section: Discussionmentioning

confidence: 99%

Sophora japonica extracts accelerates keratinocyte differentiation through miR-181a

Kim¹,

Jun

Joo³

et al. 2018

biomed dermatol

View full text Add to dashboard Cite

show abstract

“…The prevalence of atopic dermatitis (AD) may vary in different countries with an increasing tendency in developed countries (Williams et al, 1999). In particular, AD in Europe and in the USA affects 10-20% of infants and 2-3% of adults (Leung et al, 2007). The cause of AD is probably associated to a variety of conditions, such as environmental and genetic factors (Cookson et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

Probiotics as a Novel Adjuvant Approach to Atopic Dermatitis

Manzotti¹,

Heffler²,

Fassio³

2014

JCI

View full text Add to dashboard Cite

Objective. The aim of this observational study is to investigate the effect of Lactobacillus rhamnosus and Bifidobacterium lactis in atopic dermatitis (AD) in the context of routine clinical practice.Materials and Methods. 107 adult subjects with documented AD receiving a symbiotic combination of Lactobacillus rhamnosus LR05, Bifidobacterium lactis BS01 and fructo-oligosaccharide (FOS) were assessed for severity of AD using the SCOring Atopic Dermatitis index (SCORAD) and Visual Analogue Scale (VAS) for AD-related global burden of the disease at baseline and after 2 and 4 months of symbiotic supplementation. Secondary evaluations involved the changes in concomitant use of corticosteroids, antihistamines drugs and calcineurin inhibitors.Results. Treatment with Lactobacillus rhamnosus and Bifidobacterium lactis significantly decreased atopic dermatitis severity (determined by SCORAD index) after 2 and 4 months of administration, while no effect was registered on the VAS score. In addition a decrease in consumption of corticosteroids, antihistamines drugs and calcineurin inhibitors was found.Conclusion. The supplementation of Lactobacillus rhamnosus LR05, Bifidobacterium lactis BS01 and fructooligosaccharide (FOS) had a positive effect with a significant reduction in SCORAD index and concomitant decrease in the use of corticosteroids, antihistamines drugs (after 2 and 4 months of treatment) and calcineurin inhibitors (after 4 months of treatment). Our data support the need of future studies to further investigate the positive effect of Lactobacillus rhamnosus LR05, Bifidobacterium lactis BS01 and fructooligosaccharide (FOS) symbiotic combination in the management of AD, with particular focus on strainspecific effects.

show abstract

“…[4,5] Management generally includes patient education, avoidance of triggers, regular use of emollient and appropriate use of topical CS. [6,7] Nevertheless, myths and non-adherence on various therapeutic aspects prevail and management of this disease remains suboptimal. [8] CS is the firstline treatment during disease flare.…”

mentioning

confidence: 99%

“…[8] CS is the firstline treatment during disease flare. [6] Steroid phobia, however, has largely restricted the usefulness and efficacy of therapeutic CS. [9][10][11][12][13] In Hong Kong, many parents would seek alternative and folklore treatment of unproven efficacy.…”

mentioning

confidence: 99%